Vijay Pande, general partner of Andreessen Horowitz, has announced that he has resigned from his role after establishing the company’s A16Z Bio + Health Strategy.
Since its founding in 2014, A16Z Bio + Health has raised four funds, including a $1.5 billion fund that closed in 2022. However, they are currently seeking a fifth fund of $500 million, $750 million. In January, A16Z Bio + Health announced that it would separately manage a $500 million biotechnology fund funded by Pharmaceutical Giant Eli Lilly.
A16Z Bio + Health supports digital health startups and businesses at the intersection of AI, computation and biology.
Pande’s investments include dedicated health, a personalized health planning provider. function health, a personalized lab test startup. And FreeName, a company that aims to detect cancer through a blood draw. Before joining Andreessen Horowitz, Pande was a professor of chemistry, structural biology, and computer science at Stanford University.
The remaining partners on the A16Z Bio + Health team are Jorge Conde, Julie Yoo and Vineeta Agarwala.